.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKesson
Baxter
US Department of Justice
Johnson and Johnson
Medtronic
Healthtrust
Julphar
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,778,324

« Back to Dashboard

Which drugs does patent 8,778,324 protect, and when does it expire?


Patent 8,778,324 protects VELTASSA and is included in one NDA.

This patent has eighty-three patent family members in sixteen countries.

Summary for Patent: 8,778,324

Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (Los Gatos, CA)
Assignee: Relypsa, Inc. (Redwood City, CA)
Application Number:13/647,690
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA► Subscribe
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA► Subscribe
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,778,324

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,192,758Ion binding compositions► Subscribe
8,889,115Ion binding polymers and uses thereof► Subscribe
8,409,561Methods and compositions for treatment of ion imbalances► Subscribe
7,429,394Ion binding compositions► Subscribe
8,216,560Ion binding polymers and uses thereof► Subscribe
8,445,014Ion binding compositions► Subscribe
8,282,913Ion binding polymers and uses thereof► Subscribe
8,147,873Methods and compositions for treatment of ion imbalances► Subscribe
7,776,319Methods and compositions for treatment of ion imbalances► Subscribe
8,282,960Ion binding compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,778,324

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria453383► Subscribe
Austria460927► Subscribe
Australia2005228696► Subscribe
Australia2005231383► Subscribe
Australia2005231424► Subscribe
Australia2010214729► Subscribe
Australia2010214732► Subscribe
Australia2012254879► Subscribe
Australia2016216697► Subscribe
BrazilPI0509331► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
Queensland Health
Covington
Colorcon
US Army
Boehringer Ingelheim
UBS
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot